The economic and health burden of disease caused by Group A Streptococcus in New Zealand.

Abstract Objectives In preparation for the future arrival of a GAS vaccine, this study estimated the economic and health burdens of GAS diseases in New Zealand (NZ). Methods The annual incidence of GAS diseases were based on extrapolation of the average number of primary healthcare episodes managed each year in general practices (2014-16) and on the average number of hospitalisations occurring each year (2005-14). Disease incidence was multiplied by the average cost of diagnosing and managing an episode of disease at each level of care to estimate the annual economic burden. Results GAS affects 1·5% of the population each year, resulting in an economic burden of NZD29·2 million (2015 costs) and inflicting a health burden of 2,373 disability-adjusted life years (DALYs). Children Conclusion Preventing GAS disease would have substantial economic and health benefits in NZ and globally.